Exicure, Inc. (NASDAQ: XCUR)

Exicure, Inc. is a biotechnology company that has transitioned from developing nucleic acid therapies to exploring strategic alternatives to maximize shareholder value. Historically, the company focused on creating therapies targeting ribonucleic acid against validated targets. However, in September 2022, Exicure significantly reduced its workforce, suspended preclinical activities, and halted all research and development. The company has since been exploring strategic alternatives, including acquisitions, raising additional capital, and forming strategic partnerships.

Exicure generates revenue through licensing agreements, royalties, and milestone payments. In February 2024, the company received a $500,000 upfront payment from a licensing agreement for patents related to one of its historical drug candidates. Additionally, Exicure recognized other income of $637,000 from the sale of samples related to the licensed product in the second quarter of 2024. In the third quarter of 2024, the company sold its historical biotechnology intellectual property and other assets, recognizing other income of $1,500,000. The company also entered into a License and Collaboration Agreement with GPCR Therapeutics Inc., which requires milestone payments and recurring royalty payments.

• Licensing and Royalties: Exicure's revenue primarily comes from licensing agreements and royalties. The company has licensed its historical drug candidates and intellectual property to other entities, receiving upfront payments, milestone payments, and royalties on future sales. This segment caters to the biotechnology and pharmaceutical industries, providing them with access to Exicure's proprietary technologies and patents.

• Strategic Alternatives: Exicure is actively exploring strategic alternatives to maximize shareholder value. This includes acquisitions, raising additional capital, and forming strategic partnerships. The company is considering transactions in various industries, with a focus on Asia, where its significant investors and board members have relationships and business connections. This segment caters to potential partners and investors interested in joining or investing in a publicly-traded organization.

Exicure operates in a highly competitive industry, facing competition from both large and small biotechnology companies, academic institutions, government agencies, and public and private research institutions. Many of these competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Despite this competitive landscape, Exicure's strategic focus on licensing agreements, royalties, and milestone payments allows it to leverage its historical intellectual property and patents without the need for substantial internal research and development efforts.

The company's customer base primarily consists of biotechnology and pharmaceutical companies interested in licensing its proprietary technologies and patents. Additionally, Exicure is exploring strategic partnerships and acquisitions, which may involve potential partners and investors from various industries. The company's focus on Asia also suggests a potential customer base in that region, where its significant investors and board members have established relationships and business connections.